For dermatologists & clinicians
Adherence is a vehicle problem.
Your protocols specify the molecule, the strength and the frequency. They rarely specify the delivery system, and that is often why patients stop in week three.
01 Clinical adherence data
What the cetosomal vehicle data show
In the only randomised comparison published, 9% of patients using cetosomal 5% minoxidil reported adverse events versus 41% using an alcohol-based solution (p = 0.02). Quality of life improved in 78% versus 41%. A 261-patient real-world study across 66 Indian centres reported one treatment-related adverse event, and 64–69% rated tolerability excellent.
261
patients, 66 centres, retrospective[2]
0.3%
treatment-related adverse events (1 of 261)
64–69%
rated tolerability "excellent"
64–74%
rated cosmetic acceptability "excellent"
02 Why it matters to your protocols
Patients abandon the vehicle, not the molecule.
Local irritation is the leading adverse effect of topical retinoids and a common early complaint with azelaic acid and alcohol-based minoxidil. Benefit appears only after 8–12 weeks, so irritation in weeks one to four is when patients stop. Choosing a better-tolerated vehicle is a direct, low-risk way to protect adherence.
Retinoids
Retinoid dermatitis
Dryness, peeling and erythema are the most common adverse effects, and are worst early on.[3][4]
Azelaic acid
Burning & stinging
Application-site burning and itching are reported from the earliest clinical reviews.[5]
Minoxidil
Solvent irritation
Alcohol- and propylene glycol-based vehicles drive pruritus and flaking. Cetosomal vehicles avoid both.[1]
03 Downloadable dossier
Patent & literature dossier
The clinician dossier collects the two granted US patents behind the Cetosome® platform, the two peer-reviewed cetosomal clinical studies indexed in PubMed, and the supporting literature on vesicle delivery and topical tolerability. Download the reference list for Zotero, EndNote or Mendeley, or open the print-ready dossier and save it as a PDF.
04 Dispensing ecosystem
Formulations utilizing Cetosomes®
Cetosome® technology reaches patients in two ways. Prescription formulations, such as cetosomal 5% minoxidil, are marketed through established Indian pharmaceutical companies. A dedicated dermatological skincare range dispenses Cetosome®-powered formulations through clinics. Investigational analgesic compositions remain in development. The table lists each class with its evidence and access route.
Cetosome®-based prescription formulations have been brought to Indian dermatology by established pharmaceutical companies, including Sun Pharma, Glenmark and GSK. Alongside them, Monoskin offers a dedicated dermatological range built on the same platform.
| Formulation class | Active(s) | Published evidence | Access |
|---|---|---|---|
| Cetosomal minoxidil 5% solution | Minoxidil | RCT, n = 80/40[1]; real-world, n = 132 arm[2] | Prescription, dermatology |
| Cetosomal minoxidil 5% + finasteride 0.1% | Minoxidil + finasteride | Real-world, n = 129 arm[2] | Prescription, dermatology |
| Dermatological skincare range | Acne, pigmentation, barrier-repair and hair actives | Platform patents[6][7]; vehicle tolerability data | Clinics and Monoskin (monoskin.com) |
| Analgesic cetosome cream (investigational) | NSAID | Phase 2, n = 100 (patent example)[6] | Not marketed |
Clinics that want to stock or prescribe the range can reach the Monoskin clinic team at monoskin.com, or .
Clinician desk
Request literature, samples or formulation details
The formulation desk responds to dermatologists, pharmacists and R&D teams on WhatsApp.
Frequently asked
What clinical evidence exists for cetosomal formulations?
Two peer-reviewed studies of cetosomal 5% minoxidil. A randomised, open-label comparison with alcohol-based minoxidil (80 enrolled, 40 analysed) found adverse events in 9% versus 41% of patients (p = 0.02). A 261-patient retrospective study across 66 centres reported one treatment-related adverse event (0.3%).
Should dermatologists switch patients to encapsulated vehicles?
Consider it for patients who stopped or are struggling with a conventional vehicle because of stinging, dryness or scalp irritation, and for patients with barrier-impaired skin. The active and diagnosis still come first; the vehicle choice addresses tolerability and adherence.
References
- Sattur S, Talathi A, Shetty G, Arsiwala S, Pereira R, Dhoot D. Comparative Clinical Study Evaluating the Efficacy and Safety of Topical 5% Cetosomal Minoxidil and Topical 5% Alcohol-Based Minoxidil Solutions for the Treatment of Androgenetic Alopecia in Indian Men. Cureus 15(10):e46568. 2023.DOI 10.7759/cureus.46568 · PMID 37937040 · PMC10626207Randomised, open-label, 5 centres; 80 enrolled, 40 analysed. One author employed by the product's marketing company.
- Kerure A, Ghalla M, Mahajan S, Dhoot D, Barkate H. Real-World Effectiveness, Safety, and Tolerability of Cetosomal Minoxidil 5% Alone and a Fixed Drug Combination of Cetosomal Minoxidil 5% With Finasteride 0.1% in the Management of Androgenetic Alopecia (Inbilt Study). Cureus 15(7):e41681. 2023.DOI 10.7759/cureus.41681 · PMID 37575862 · PMC10413304Retrospective, 66 centres, n = 261. Industry-affiliated authors (employees of the product's marketing company).
- Zaenglein AL, Pathy AL, Schlosser BJ, et al. Guidelines of care for the management of acne vulgaris. Journal of the American Academy of Dermatology 74(5):945–973.e33. 2016.DOI 10.1016/j.jaad.2015.12.037
- Mukherjee S, Date A, Patravale V, Korting HC, Roeder A, Weindl G. Retinoids in the treatment of skin aging: an overview of clinical efficacy and safety. Clinical Interventions in Aging 1(4):327–348. 2006.DOI 10.2147/ciia.2006.1.4.327
- Fitton A, Goa KL. Azelaic Acid: A review of its pharmacological properties and therapeutic efficacy in acne and hyperpigmentary skin disorders. Drugs 41(5):780–798. 1991.DOI 10.2165/00003495-199141050-00007
- Barathur RR, Bookout JB (assignee: Cymbiotics, Inc.). Topical dermal delivery compositions using self assembling nanoparticles with cetylated components. US Patent US 9,084,818 B2. 2015.Filed 15 Feb 2013; granted 21 Jul 2015. Claim 1 specifies nanoparticle zeta potential of −20 to −100 mV (or +20 to +100 mV). Measured particle diameters of 60–850 nm; claimed physical dimensions 30 nm–5 µm.
- Barathur RR, Bookout JB (assignee: Cymbiotics, Inc.). Transdermal delivery of medicaments with combinations of cetylated fatty ester penetrant complexes. US Patent US 8,394,759 B2. 2013.Priority 21 Nov 2008; filed 29 Oct 2009; granted 12 Mar 2013. Foundational cetylated-fatty-ester penetrant work, incorporated by reference into US 9,084,818 B2.
Methodology
Content is written from primary sources: granted US patent text, peer-reviewed journals indexed in PubMed or Crossref, and regulator publications. Numerical specifications are quoted exactly as reported in the cited source. Where data are illustrative models rather than measurements, the figure says so.
Conflict of interest & scope
Cetosomes.com is operated in association with parties that manufacture and dispense Cetosome®-based formulations. This site explains vehicle and delivery biophysics; it does not diagnose, treat or prescribe. Clinical decisions belong to a qualified dermatologist or physician. Research articles in the Journal carry no product or brand references.
